Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Quest Diagnostics, Inc (NYSE: DGX) closed the day trading at $183.77 down -2.86% from the previous closing price of $189.18. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 1.16 million shares were traded. DGX stock price reached its highest trading level at $189.385 during the session, while it also had its lowest trading level at $183.66.
Ratios:
For a better understanding of DGX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 47.32 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.68. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.13. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
On April 02, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $195. Citigroup Downgraded its Buy to Neutral on March 04, 2025, while the target price for the stock was maintained at $185.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when Davis J. E. sold 55,093 shares for $192.22 per share. The transaction valued at 10,589,760 led to the insider holds 120,480 shares of the business.
Gregg Vicky B sold 1,250 shares of DGX for $239,700 on Nov 25 ’25. The Director now owns 17,037 shares after completing the transaction at $191.76 per share. On Nov 25 ’25, another insider, Davis J. E., who serves as the Officer of the company, bought 55,093 shares for $192.22 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 20549793792 and an Enterprise Value of 26508009472. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.56, and their Forward P/E ratio for the next fiscal year is 17.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.88 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 2.443 whereas that against EBITDA is 12.381.
Stock Price History:
The Beta on a monthly basis for DGX is 0.62, which has changed by 0.13480306 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $197.55, while it has fallen to a 52-week low of $148.70. The 50-Day Moving Average of the stock is -0.21%, while the 200-Day Moving Average is calculated to be 4.09%.
Shares Statistics:
Over the past 3-months, DGX traded about 998.44K shares per day on average, while over the past 10 days, DGX traded about 1212130 shares per day. A total of 111.00M shares are outstanding, with a floating share count of 110.73M. Insiders hold about 0.46% of the company’s shares, while institutions hold 97.63% stake in the company. Shares short for DGX as of 1763078400 were 4294155 with a Short Ratio of 4.30, compared to 1760486400 on 3949817. Therefore, it implies a Short% of Shares Outstanding of 4294155 and a Short% of Float of 4.4099998000000005.
Dividends & Splits
DGX’s forward annual dividend rate is 3.15, up from 3.15 a year ago. Against a Trailing Annual Dividend Yield of 0.016650809. The stock’s 5-year Average Dividend Yield is 1.86. The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-10-03 with an ex-dividend date of 2026-01-13. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
The stock of Quest Diagnostics, Inc (DGX) is currently drawing attention from 14.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $2.36, with high estimates of $2.55 and low estimates of $2.18.
Analysts are recommending an EPS of between $9.88 and $9.76 for the fiscal current year, implying an average EPS of $9.81. EPS for the following year is $10.37, with 17.0 analysts recommending between $10.74 and $9.87.
Revenue Estimates
12 analysts predict $2.75B in revenue for. The current quarter. It ranges from a high estimate of $2.77B to a low estimate of $2.73B. As of. The current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.62BFor the next quarter, 12 analysts are estimating revenue of $2.76B. There is a high estimate of $2.8B for the next quarter, whereas the lowest estimate is $2.72B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $11B, while the lowest revenue estimate was $10.96B, resulting in an average revenue estimate of $10.98B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.38B in the next fiscal year. The high estimate is $11.57B and the low estimate is $11.23B.
